بدائل البحث:
significant source » significant burden (توسيع البحث)
we decrease » _ decrease (توسيع البحث), a decrease (توسيع البحث), mean decrease (توسيع البحث)
nn decrease » _ decrease (توسيع البحث), a decrease (توسيع البحث), mean decrease (توسيع البحث)
significant source » significant burden (توسيع البحث)
we decrease » _ decrease (توسيع البحث), a decrease (توسيع البحث), mean decrease (توسيع البحث)
nn decrease » _ decrease (توسيع البحث), a decrease (توسيع البحث), mean decrease (توسيع البحث)
-
241
Table 1_Multi-generational adaptation to Solanum nigrum increases reproduction and decreases microbial diversity of Aphis gossypii.docx
منشور في 2025"…The relative abundance of Buchnera in T5 and T10 significantly increased compared to M and T, while the relative abundance of Arsenophonus decreased markedly. …"
-
242
-
243
-
244
-
245
-
246
-
247
-
248
-
249
-
250
-
251
-
252
-
253
-
254
-
255
Table_1_FMT intervention decreases urine 5-HIAA levels: a randomized double-blind controlled study.DOCX
منشور في 2024"…However, in the placebo group, GSRS, CARS, and SRS scores showed no significant changes, while ABC scores decreased from 72 to 58.75 (p = 0.034). …"
-
256
-
257
-
258
Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
منشور في 2025"…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…"
-
259
Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
منشور في 2025"…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…"
-
260
Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
منشور في 2025"…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…"